A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 84-90

  Yoshida, Hideo ^a   Itoh, Shinsuke ^a   Hara, Takuya ^a   Sasaki, Yusuke ^a   Kondo, Shoichi ^a   Nakagawa, Takashi ^a   Asanuma, Akimune ^a   Tanabe, Sohei ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

Blood flow; Ischemia; PDE3 inhibitor; Peripheral arterial disease; Peripheral vasculature; Platelet

Indexed keywords

ANTITHROMBOCYTIC AGENT; K 134; PHOSPHODIESTERASE III INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY DILATATION; ARTERY OCCLUSION; ARTICLE; BLOOD VESSEL INJURY; CAPILLARY DENSITY; CELL PROLIFERATION; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROSTIMULATION; EXERCISE; GASTROCNEMIUS MUSCLE; HINDLIMB; IN VITRO STUDY; LONG TERM CARE; MALE; MICROCIRCULATION; MUSCLE BLOOD FLOW; MUSCLE NECROSIS; NERVE STIMULATION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SMOOTH MUSCLE RELAXATION; THROMBOCYTE AGGREGATION; TIBIALIS ANTERIOR MUSCLE; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD FLOW VELOCITY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB; LAURIC ACIDS; MALE; MUSCLE, SKELETAL; NECROSIS; PERIPHERAL ARTERIAL DISEASE; PHOSPHODIESTERASE 3 INHIBITORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; TIME FACTORS; UREA; VASCULAR SYSTEM INJURIES; VASODILATION; VASODILATOR AGENTS;

EID: 84857034598     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.044     Document Type: Article

References (24)

1. Norgren L., Hiatt W.R., Dormandy J.A., et al. The Trans-Atlantic Inter-Society Consensus (TASC II): document on management of peripheral arterial disease. Eur J Vasc Endovasc Surg 2007, 33(Suppl 1):S1-S75.
2. Meru A.V., Mittra S., Thyagarajan B., et al. Intermittent claudication: an overview. Atherosclerosis 2006, 187:221-237.
3. Libby P., Ridker P.M., Hansson G.K., et al. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
4. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008, 263:517-527.
5. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006, 58:488-520.
6. Yoshida H., Okamura Y., Watanabe N., et al. Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation. Thromb Haemost 2011, 105:487-495.
7. Tanaka T., Ishikawa T., Hagiwara M., et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988, 36:313-320.
8. Ishiwata N., Noguchi K., Kawanishi M., et al. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model. Life Sci 2007, 81:970-978.
9. Herzog S., Sager H., Khmelevski E., et al. Collateral arteries grow from preexisting anastomoses in the rat hindlimb. Am J Physiol Heart Circ Physiol 2002, 283:H2012-H2020.
10. Hollenberg N.K. Implications of thrombosis and vasospasm in peripheral vascular disease. J Cardiovasc Pharmacol 1991, 17(Suppl 5):S21-S28.
11. Akiyama H., Kudo S., Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 1985, 35:1133-1140.
12. Brevetti L.S., Paek R., Brady S.E., et al. Exercise-induced hyperemia unmasks regional blood flow deficit in experimental hindlimb ischemia. J Surg Res 2001, 98:21-26.
13. Ashida S., Ishihara M., Ogawa H., et al. Protective effect of ticlopidine on experimentally induced peripheral arterial occlusive disease in rats. Thromb Res 1980, 18:55-67.
14. Uemura T., Takamatsu H., Kawasaki T., et al. Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats. Eur J Pharmacol 2006, 536:154-161.
15. Abiru T., Endo K., Machida H. Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A2 receptor agonist, in the isolated rat femoral artery and vein. Eur J Pharmacol 1995, 281:9-15.
16. Ciccarelli M., Santulli G., Campanile A., et al. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 2008, 153:936-946.
17. Iaccarino G., Ciccarelli M., Sorriento D., et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005, 97:1182-1189.
18. Lee E.W., Michalkiewicz M., Kitlinska J., et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003, 111:1853-1862.
19. Sette C., Vicini E., Conti M. Modulation of cellular responses by hormones: role of cAMP specific, rolipram-sensitive phosphodiesterases. Mol Cell Endocrinol 1994, 100:75-79.
20. Nakaya K., Ayaori M., Uto-Kondo H., et al. Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo. Atherosclerosis 2010, 213:135-141.
21. Okutsu R., Yoshikawa T., Nagasawa M., et al. Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. Atherosclerosis 2009, 204:405-411.
22. Park S.Y., Lee J.H., Kim K.Y., et al. Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription. Atherosclerosis 2008, 201:258-265.
23. Hashimoto A., Miyakoda G., Hirose Y., et al. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006, 189:350-357.
24. Bramer S.L., Forbes W.P., Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999, 37(Suppl 2):1-11.